Creso Pharma (ASX:CPH) to commence phase II clinical trials

Creso Pharma Ltd (ASX: CPH) and its target acquisition company, Halucenex, have taken the first steps for its phase II clinical trial.
The post Creso Pharma (ASX:CPH) to commence phase II clinical trials appeared first on The Motley Fool Australia. –

Biotechnology graphics

Creso Pharma Ltd (ASX: CPH) announced today that its target acquisition company Halucenex Life Sciences has made progress in the commencement of a significant phase II clinical trial.  

Creso advised that Halucenex has appointed leading research provider True North Clinical Research as the principal investigator to test the efficacy and safety of psilocybin for the treatment of treatment-resistant post-traumatic stress disorder (PTSD) in veterans and first responders.

Creso Pharma acquires Halucenex 

On 15 March, Creso Pharma announced the acquisition of Halucenex. Halucenex is focused on researching, developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets. Creso Pharma sees this as an opportunity to enter the emerging global market for psychedelic medicines, which is estimated to be worth up to US$100 billion. 

Creso Pharma describes the acquisition as “transformational” and a “first-mover advantage” to emerge as the first 100%-owned psychedelic medicines company on the ASX. The acquisition would allow the company to extend its product suite to include cannabis, cannabinoids, and psychedelic alternative medicines.

Halucenex phase II clinical trial

The phase II trial will enroll approximately 18 to 20 subjects with treatment resistant PTSD. As the lead investigators, True North will provide clinical oversight with core activities including patient recruitment, conduct the trial, monitoring, data capture and compilation of results. True North was selected to lead the trials given its favourable geographic location for participants and considerable experience in providing patient care. 

The phase II trial will involve patients receiving two oral doses of psilocybin separated by 7 days. The patients will be closely monitored in the clinic by the study monitors during the hallucinogenic period. The trials will be used to determine the feasibility of future trials of psilocybin. 

The company expects the trials to commence in June 2021, subject to a pending Clinical Trial Authorisation Permit from Health Canada. Halucenex intends to lodge the required documentation by the end of April 2021. 

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Creso Pharma (ASX:CPH) to commence phase II clinical trials appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!